▲ Peaking
Business
🔮 fades
AbbVie sharpens immunology focus with $10.9 billion Apogee deal
AbbVie is acquiring Waltham-based biotech firm Apogee Therapeutics in a deal valued at $10.9 billion to bolster its immunology drug portfolio.